This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Valuing Snap After the IPO Quiet Period (C)
Di Maggio, Marco; Esty, Benjamin C.; Saldutte, GregCase HBS-218116-EFinanceAnalyzes Snap's value and analyst recommendations following the events described in the B case.Starting at €5.74
-
Valuing Snap After the IPO Quiet Period (A), (B), and (C), Teaching Note
Di Maggio, Marco; Esty, Benjamin C.Teaching Note HBS-218101-EFinanceTeaching note for cases 218095, 218096, and 218116.Starting at €0.00
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Case HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Starting at €8.20
-
Gilead: Hepatitis C Access Strategy (B)
Rangan, V. KasturiCase HBS-515044-EWhile the Gilead: Hepatitis-C Access Strategy (A) case (515-025) poses questions on what the company should do with respect to hart hit countries like Egypt and India, this (B) case provides the answer. In both cases, the company chose to pursue a proactive strategy to enable access at affordable prices.Starting at €5.74
-
Equitas Microfinance (C): Advent of Regulation
Narayanan, V.G.; Rangan, V. Kasturi; Muthuram, VidhyaCase HBS-113006-ESupplement for case 510104Starting at €5.74
-
Atlas-Copco (C): El episodio del conflicto
Rangan, V. KasturiCase HBS-509S23MarketingDescribe la respuesta de la empresa a otros problemas con un distribuidor.Starting at €5.74
-
Gilead: Hepatitis-C Access Strategy (A) and (B), Teaching Plan
Rangan, V. KasturiTeaching Note HBS-520063-ETeaching plan for cases 515025 and 515044.Starting at €0.00
-
Valuing Snap After the IPO Quiet Period (B)
Di Maggio, Marco; Esty, Benjamin C.Case HBS-218096-EFinanceAnalyzes Snap's value and analyst recommendations following the events described in the A case.Starting at €5.74
-
General Electric Plastics: Organización de la Función Comercial
Rangan, V. Kasturi; Michael, Steven C.Case HBS-505S18MarketingDescribe el rápido crecimiento de General Electric Plastics de durante la última década a un (ventas) compañía de $ 5 mil millones. Se describen las transiciones de organización de acompañamiento. La tarea es diseñar una organización de marketing para la próxima década debido a los cambios de mercado previstos.Starting at €8.20
-
Valuing Snap After the IPO Quiet Period (A)
Di Maggio, Marco; Esty, Benjamin C.; Saldutte, GregCase HBS-218095-EFinanceSnap, the disappearing message app, went public at $17 per share on March 2, 2017, making its two 20-something founders the youngest self-made billionaires in the country. Over the next three weeks, 14 analysts made investment recommendations on Snap: twoStarting at €8.20